Business Description
Rhythm Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US76243J1051
Total Employee Number:
414Compare
Compare
Traded in other countries / regions
RYTM.USA1RV.GermanyRYTM.Mexico Index Membership
Russell 2000Russell 3000 IPO Date
2017-10-05Description
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 89.87 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 15.44 | |||||
Beneish M-Score | -3.07 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 86 | |||||
3-Year EBITDA Growth Rate | 7.1 | |||||
3-Year EPS without NRI Growth Rate | 3.6 | |||||
3-Year FCF Growth Rate | 19.3 | |||||
3-Year Book Growth Rate | -23.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 68.55 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.95 | |||||
9-Day RSI | 38.15 | |||||
14-Day RSI | 44.19 | |||||
3-1 Month Momentum % | 16.2 | |||||
6-1 Month Momentum % | 16.51 | |||||
12-1 Month Momentum % | 3.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.45 | |||||
Quick Ratio | 3.2 | |||||
Cash Ratio | 2.68 | |||||
Days Inventory | 348.28 | |||||
Days Sales Outstanding | 48.63 | |||||
Days Payable | 199.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.9 | |||||
Shareholder Yield % | -2.56 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 89 | |||||
Operating Margin % | -83.62 | |||||
Net Margin % | -85.59 | |||||
EBITDA Margin % | -76.99 | |||||
FCF Margin % | -43.91 | |||||
OCF Margin % | -43.91 | |||||
ROE % | -88.96 | |||||
ROA % | -45.85 | |||||
ROIC % | -598.85 | |||||
3-Year ROIIC % | 176.51 | |||||
ROC (Joel Greenblatt) % | -5153.01 | |||||
ROCE % | -55.53 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 29.82 | |||||
PB Ratio | 70.75 | |||||
Price-to-Tangible-Book | 74.22 | |||||
EV-to-EBIT | -38.18 | |||||
EV-to-Forward-EBIT | 12.41 | |||||
EV-to-EBITDA | -38.41 | |||||
EV-to-Revenue | 29.57 | |||||
EV-to-Forward-Revenue | 23.84 | |||||
EV-to-FCF | -67.34 | |||||
Price-to-GF-Value | 0.87 | |||||
| Price-to-Net-Current-Asset-Value | 79.2 | |||||
| Price-to-Net-Cash | 65.92 | |||||
Earnings Yield (Greenblatt) % | -2.62 | |||||
FCF Yield % | -1.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RYTM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rhythm Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 239.918 | ||
| EPS (TTM) ($) | -3.11 | ||
| Beta | 1.3198 | ||
| 3-Year Sharpe Ratio | 1.18 | ||
| 3-Year Sortino Ratio | 3.69 | ||
| Volatility % | 42.03 | ||
| 14-Day RSI | 44.19 | ||
| 14-Day ATR ($) | 4.714191 | ||
| 20-Day SMA ($) | 112.31275 | ||
| 12-1 Month Momentum % | 3.66 | ||
| 52-Week Range ($) | 74.5 - 122.2 | ||
| Shares Outstanding (Mil) | 68.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rhythm Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rhythm Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 08:00 | In 180 days | ||
| Annual report for 2026 | 2027-02-26 | In 179 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 179 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 08:00 | In 66 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 65 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-15 13:50 | In 16 days | ||
| Wells Fargo 21st Annual Healthcare Conference | 2026-09-09 15:00 | In 10 days | ||
| the Canaccord Genuity 46th Annual Growth Conference | 2026-08-12 09:00 | 112.85 (-0.29%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 08:00 | 102.78 (+2.38%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 102.78 (+2.38%) |
Show
Entries
Rhythm Pharmaceuticals Inc Frequently Asked Questions
What is Rhythm Pharmaceuticals Inc(RYTM)'s stock price today?
The current price of RYTM is $106.13. The 52 week high of RYTM is $122.20 and 52 week low is $74.50.
When is next earnings date of Rhythm Pharmaceuticals Inc(RYTM)?
The next earnings date of Rhythm Pharmaceuticals Inc(RYTM) is 2026-11-04 Est..
Does Rhythm Pharmaceuticals Inc(RYTM) pay dividends? If so, how much?
Rhythm Pharmaceuticals Inc(RYTM) does not pay dividend.
Guru Commentaries on NAS:RYTM
2025 Q3
What the manager wrote
Rhythm Pharmaceuticals delivered on positive data and commercial catalysts, contributing to the overall strong performance in the biotech sector. The company is well-positioned to benefit from improving investor sentiment and positive trial results, which have been significant drivers in the recent gains within the industry. As the biotech index gained approximately 22%, Rhythm's performance reflects its potential for continued growth in a favorable market environment.
2025 Q2
What the manager wrote
Rhythm Pharmaceuticals is a biopharmaceutical company focused on metabolic conditions related to genetic/injury-related obesity. The company has launched its main product in several rare indications, with likely approval for launching into a much larger indication in the near term. With a variety of pipeline candidates to enhance lifecycle management and address other related illnesses, we see robust growth potential ahead.
Press Release
Articles on Rhythm Pharmaceuticals Inc
PERCEPTIVE ADVISORS LLC Expands Relay Therapeutics Inc (RLAY) Stake -- Shares Look 421% Overvalued on GF Value
Aug 15, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers